Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target

Influenza A virus (IAV) causes annual epidemics and development of antivirals is needed. Here, the authors perform phosphoproteomics during IAV entry and identify GRK2 as drug target, inhibition of which decreases replication of seasonal and pandemic IAV in primary human cells and animal models.

Guardado en:

Detalles Bibliográficos
Autores principales:	Emilio Yángüez, Annika Hunziker, Maria Pamela Dobay, Soner Yildiz, Simon Schading, Elizaveta Elshina, Umut Karakus, Peter Gehrig, Jonas Grossmann, Ronald Dijkman, Mirco Schmolke, Silke Stertz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/75fc5e0fffec45b99c4b42c17dc10447
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75fc5e0fffec45b99c4b42c17dc10447
record_format	dspace
spelling	oai:doaj.org-article:75fc5e0fffec45b99c4b42c17dc104472021-12-02T16:56:44ZPhosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target10.1038/s41467-018-06119-y2041-1723https://doaj.org/article/75fc5e0fffec45b99c4b42c17dc104472018-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06119-yhttps://doaj.org/toc/2041-1723Influenza A virus (IAV) causes annual epidemics and development of antivirals is needed. Here, the authors perform phosphoproteomics during IAV entry and identify GRK2 as drug target, inhibition of which decreases replication of seasonal and pandemic IAV in primary human cells and animal models.Emilio YángüezAnnika HunzikerMaria Pamela DobaySoner YildizSimon SchadingElizaveta ElshinaUmut KarakusPeter GehrigJonas GrossmannRonald DijkmanMirco SchmolkeSilke StertzNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Emilio Yángüez Annika Hunziker Maria Pamela Dobay Soner Yildiz Simon Schading Elizaveta Elshina Umut Karakus Peter Gehrig Jonas Grossmann Ronald Dijkman Mirco Schmolke Silke Stertz Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
description	Influenza A virus (IAV) causes annual epidemics and development of antivirals is needed. Here, the authors perform phosphoproteomics during IAV entry and identify GRK2 as drug target, inhibition of which decreases replication of seasonal and pandemic IAV in primary human cells and animal models.
format	article
author	Emilio Yángüez Annika Hunziker Maria Pamela Dobay Soner Yildiz Simon Schading Elizaveta Elshina Umut Karakus Peter Gehrig Jonas Grossmann Ronald Dijkman Mirco Schmolke Silke Stertz
author_facet	Emilio Yángüez Annika Hunziker Maria Pamela Dobay Soner Yildiz Simon Schading Elizaveta Elshina Umut Karakus Peter Gehrig Jonas Grossmann Ronald Dijkman Mirco Schmolke Silke Stertz
author_sort	Emilio Yángüez
title	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
title_short	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
title_full	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
title_fullStr	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
title_full_unstemmed	Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
title_sort	phosphoproteomic-based kinase profiling early in influenza virus infection identifies grk2 as antiviral drug target
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/75fc5e0fffec45b99c4b42c17dc10447
work_keys_str_mv	AT emilioyanguez phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT annikahunziker phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT mariapameladobay phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT soneryildiz phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT simonschading phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT elizavetaelshina phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT umutkarakus phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT petergehrig phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT jonasgrossmann phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT ronalddijkman phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT mircoschmolke phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget AT silkestertz phosphoproteomicbasedkinaseprofilingearlyininfluenzavirusinfectionidentifiesgrk2asantiviraldrugtarget
_version_	1718382746442661888

Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target

Ejemplares similares